Dehydroepiandrosterone inhibits B16 mouse melanoma cell growth by induction of differentiation. 1995

S Kawai, and N Yahata, and S Nishida, and K Nagai, and Y Mizushima
Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.

BACKGROUND Low serum concentrations of dehydroepiandrosterone (DHEA) and its sulfate are associated with an increased incidence of various human malignancies. DHEA has chemopreventive and antiproliferative effects in experimental studies. Accordingly, the effects of DHEA on B16 mouse melanoma cells were studied. METHODS The effects of DHEA on cell number and melanin production of the melanoma cells were measured. Specific DHEA receptor was detected by a cytosol binding assay. Protein kinase C (PKC) activity of the melanoma cells was detected by phosphorylation of PKC specific substrate. RESULTS DHEA dose-dependently inhibited the growth of melanoma cells and enhanced melanin production, which indicated the induction of differentiation. There was a [3H]DHEA specific binding protein in the melanoma cell cytosol. Although DHEA did not promote the translocation of PKC from the cytosolic to the membrane fraction, the total PKC activity was upregulated by treatment with DHEA. CONCLUSIONS DHEA inhibited the growth of B16 mouse melanoma cells by the induction of differentiation, possibly related to PKC upregulation mediated by DHEA receptor.

UI MeSH Term Description Entries
D008543 Melanins Insoluble polymers of TYROSINE derivatives found in and causing darkness in skin (SKIN PIGMENTATION), hair, and feathers providing protection against SUNBURN induced by SUNLIGHT. CAROTENES contribute yellow and red coloration. Allomelanins,Melanin,Phaeomelanins
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011493 Protein Kinase C An serine-threonine protein kinase that requires the presence of physiological concentrations of CALCIUM and membrane PHOSPHOLIPIDS. The additional presence of DIACYLGLYCEROLS markedly increases its sensitivity to both calcium and phospholipids. The sensitivity of the enzyme can also be increased by PHORBOL ESTERS and it is believed that protein kinase C is the receptor protein of tumor-promoting phorbol esters. Calcium Phospholipid-Dependent Protein Kinase,Calcium-Activated Phospholipid-Dependent Kinase,PKC Serine-Threonine Kinase,Phospholipid-Sensitive Calcium-Dependent Protein Kinase,Protein Kinase M,Calcium Activated Phospholipid Dependent Kinase,Calcium Phospholipid Dependent Protein Kinase,PKC Serine Threonine Kinase,Phospholipid Sensitive Calcium Dependent Protein Kinase,Phospholipid-Dependent Kinase, Calcium-Activated,Serine-Threonine Kinase, PKC
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D003600 Cytosol Intracellular fluid from the cytoplasm after removal of ORGANELLES and other insoluble cytoplasmic components. Cytosols

Related Publications

S Kawai, and N Yahata, and S Nishida, and K Nagai, and Y Mizushima
April 1982, Journal of the National Cancer Institute,
S Kawai, and N Yahata, and S Nishida, and K Nagai, and Y Mizushima
October 1989, Cancer letters,
S Kawai, and N Yahata, and S Nishida, and K Nagai, and Y Mizushima
March 2009, Ai zheng = Aizheng = Chinese journal of cancer,
S Kawai, and N Yahata, and S Nishida, and K Nagai, and Y Mizushima
May 2002, Japanese journal of cancer research : Gann,
S Kawai, and N Yahata, and S Nishida, and K Nagai, and Y Mizushima
October 2000, The British journal of dermatology,
S Kawai, and N Yahata, and S Nishida, and K Nagai, and Y Mizushima
September 2003, Journal of biochemistry,
S Kawai, and N Yahata, and S Nishida, and K Nagai, and Y Mizushima
January 1989, Pigment cell research,
S Kawai, and N Yahata, and S Nishida, and K Nagai, and Y Mizushima
August 2021, Bioelectrochemistry (Amsterdam, Netherlands),
S Kawai, and N Yahata, and S Nishida, and K Nagai, and Y Mizushima
February 2021, Molecules (Basel, Switzerland),
S Kawai, and N Yahata, and S Nishida, and K Nagai, and Y Mizushima
July 2013, Planta medica,
Copied contents to your clipboard!